View in EDS

Overall survival in patients with hormone receptor-positive, HER2-negative advanced breast cancer treated in a phase 1b trial evaluating gedatolisib in combination with palbociclib and endocrine therapy.

Saved in:
Bibliographic Details
Title: Overall survival in patients with hormone receptor-positive, HER2-negative advanced breast cancer treated in a phase 1b trial evaluating gedatolisib in combination with palbociclib and endocrine therapy.
Authors: Layman RM; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: rlayman@mdanderson.org., Han HS; Moffit Cancer Center, Tampa, FL, USA., Rugo HS; Division of Hematology and Oncology, University of California, San Francisco Comprehensive Cancer Center, San Francisco, CA, USA., Stringer-Reasor EM; Division of Hematology Oncology, Department of Medicine, O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA., Specht JM; Division of Hematology and Oncology, Fred Hutchinson Cancer Center, University of Washington, Seattle, WA, USA., Dees EC; Division of Oncology, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA., Kabos P; Division of Medical Oncology, University of Colorado Hospital, Aurora, CO, USA., Suzuki S; Celcuity, Minneapolis, MN, USA., Mutka SC; Celcuity, Minneapolis, MN, USA., Sullivan BF; Celcuity, Minneapolis, MN, USA., Gorbatchevsky I; Celcuity, Minneapolis, MN, USA., Wesolowski R; Department of Internal Medicine, Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Source: The Lancet. Oncology [Lancet Oncol] 2025 Jul; Vol. 26 (7), pp. e332-e333.
Publication Type: Letter
Journal Info: Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE; In Process
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 40609573
AccessLevel: 2
PubType: Editorial & Opinion
PubTypeId: editorialOpinion
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Overall survival in patients with hormone receptor-positive, HER2-negative advanced breast cancer treated in a phase 1b trial evaluating gedatolisib in combination with palbociclib and endocrine therapy.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Layman+RM%22">Layman RM</searchLink>; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: rlayman@mdanderson.org.<br /><searchLink fieldCode="AU" term="%22Han+HS%22">Han HS</searchLink>; Moffit Cancer Center, Tampa, FL, USA.<br /><searchLink fieldCode="AU" term="%22Rugo+HS%22">Rugo HS</searchLink>; Division of Hematology and Oncology, University of California, San Francisco Comprehensive Cancer Center, San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Stringer-Reasor+EM%22">Stringer-Reasor EM</searchLink>; Division of Hematology Oncology, Department of Medicine, O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA.<br /><searchLink fieldCode="AU" term="%22Specht+JM%22">Specht JM</searchLink>; Division of Hematology and Oncology, Fred Hutchinson Cancer Center, University of Washington, Seattle, WA, USA.<br /><searchLink fieldCode="AU" term="%22Dees+EC%22">Dees EC</searchLink>; Division of Oncology, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA.<br /><searchLink fieldCode="AU" term="%22Kabos+P%22">Kabos P</searchLink>; Division of Medical Oncology, University of Colorado Hospital, Aurora, CO, USA.<br /><searchLink fieldCode="AU" term="%22Suzuki+S%22">Suzuki S</searchLink>; Celcuity, Minneapolis, MN, USA.<br /><searchLink fieldCode="AU" term="%22Mutka+SC%22">Mutka SC</searchLink>; Celcuity, Minneapolis, MN, USA.<br /><searchLink fieldCode="AU" term="%22Sullivan+BF%22">Sullivan BF</searchLink>; Celcuity, Minneapolis, MN, USA.<br /><searchLink fieldCode="AU" term="%22Gorbatchevsky+I%22">Gorbatchevsky I</searchLink>; Celcuity, Minneapolis, MN, USA.<br /><searchLink fieldCode="AU" term="%22Wesolowski+R%22">Wesolowski R</searchLink>; Department of Internal Medicine, Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22100957246%22">The Lancet. Oncology</searchLink> [Lancet Oncol] 2025 Jul; Vol. 26 (7), pp. e332-e333.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Letter
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Lancet+Pub%2E+Group%22">Lancet Pub. Group </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>100957246 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1474-5488 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2214702045%22">14702045 </searchLink><i>NLM ISO Abbreviation: </i>Lancet Oncol <i>Subsets: </i>MEDLINE; In Process
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40609573
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/S1470-2045(25)00236-0
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: e332
    Titles:
      – TitleFull: Overall survival in patients with hormone receptor-positive, HER2-negative advanced breast cancer treated in a phase 1b trial evaluating gedatolisib in combination with palbociclib and endocrine therapy.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Layman RM
      – PersonEntity:
          Name:
            NameFull: Han HS
      – PersonEntity:
          Name:
            NameFull: Rugo HS
      – PersonEntity:
          Name:
            NameFull: Stringer-Reasor EM
      – PersonEntity:
          Name:
            NameFull: Specht JM
      – PersonEntity:
          Name:
            NameFull: Dees EC
      – PersonEntity:
          Name:
            NameFull: Kabos P
      – PersonEntity:
          Name:
            NameFull: Suzuki S
      – PersonEntity:
          Name:
            NameFull: Mutka SC
      – PersonEntity:
          Name:
            NameFull: Sullivan BF
      – PersonEntity:
          Name:
            NameFull: Gorbatchevsky I
      – PersonEntity:
          Name:
            NameFull: Wesolowski R
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 07
              Text: 2025 Jul
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1474-5488
          Numbering:
            – Type: volume
              Value: 26
            – Type: issue
              Value: 7
          Titles:
            – TitleFull: The Lancet. Oncology
              Type: main
ResultId 1